DK0566535T3 - Methandiphosphonsyre-præparater med ionbyttere - Google Patents

Methandiphosphonsyre-præparater med ionbyttere

Info

Publication number
DK0566535T3
DK0566535T3 DK93810246T DK93810246T DK0566535T3 DK 0566535 T3 DK0566535 T3 DK 0566535T3 DK 93810246 T DK93810246 T DK 93810246T DK 93810246 T DK93810246 T DK 93810246T DK 0566535 T3 DK0566535 T3 DK 0566535T3
Authority
DK
Denmark
Prior art keywords
diphosphonic acid
ion exchangers
acid preparations
disodium
methane diphosphonic
Prior art date
Application number
DK93810246T
Other languages
English (en)
Inventor
Satish Chandra Dr Khanna
Jonathan Dr Green
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK0566535T3 publication Critical patent/DK0566535T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment Of Sludge (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
DK93810246T 1992-04-15 1993-04-06 Methandiphosphonsyre-præparater med ionbyttere DK0566535T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH124792 1992-04-15

Publications (1)

Publication Number Publication Date
DK0566535T3 true DK0566535T3 (da) 2000-03-06

Family

ID=4205927

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93810246T DK0566535T3 (da) 1992-04-15 1993-04-06 Methandiphosphonsyre-præparater med ionbyttere

Country Status (20)

Country Link
US (1) US5344825A (da)
EP (1) EP0566535B1 (da)
JP (1) JP3970941B2 (da)
KR (1) KR100307786B1 (da)
AT (1) ATE183096T1 (da)
AU (1) AU665814B2 (da)
CA (1) CA2093946C (da)
DE (1) DE59309727D1 (da)
DK (1) DK0566535T3 (da)
ES (1) ES2137241T3 (da)
FI (1) FI110920B (da)
GR (1) GR3031645T3 (da)
HU (1) HU219022B (da)
IL (1) IL105382A (da)
MX (1) MX9302151A (da)
NO (1) NO306978B1 (da)
NZ (1) NZ247398A (da)
PH (1) PH30733A (da)
TW (1) TW237386B (da)
ZA (1) ZA932613B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US5591730A (en) * 1993-10-12 1997-01-07 The Regents Of The University Of California Inhibition of urinary calculi growth
US20010007863A1 (en) 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
NZ503946A (en) * 1997-06-11 2003-02-28 Procter & Gamble Oral dosage form in an oval or caplet shape for administration of bisphosphonates and other known medicaments
FI104901B (fi) 1997-10-20 2000-04-28 Leiras Oy Uudet metyleenibisfosfonihappojohdannaiset
US6160165A (en) 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
US6794536B1 (en) 1998-12-10 2004-09-21 Aesqen, Inc. Method for preparation of disodium pamidronate
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
ES2243457T3 (es) * 2001-01-23 2005-12-01 Gador S.A. Composicion que comprende bifosfonatos para la prevencion y/o tratamiento de trastornos metabolicos de huesos, procedimiento de preparacion de dicha composicion y usos de la misma.
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
US6933127B2 (en) 2001-07-05 2005-08-23 Eucro European Contract Research Gmbh & Co. Kg Substrate for PP2C
WO2003020242A1 (en) * 2001-08-29 2003-03-13 Srl Technologies, Inc. Sustained release preparations
JP2005514400A (ja) * 2001-12-21 2005-05-19 ザ プロクター アンド ギャンブル カンパニー 骨疾患の治療方法
ATE376444T1 (de) * 2002-05-10 2007-11-15 Hoffmann La Roche Ibandronsäure zur behandlung und vorbeugung von osteoporose
JP2004018524A (ja) * 2002-06-13 2004-01-22 Eucro European Contract Research Gmbh & Co Kg 動脈硬化症を処置するための方法
EP1396263A1 (en) * 2002-08-09 2004-03-10 Warner-Lambert Company Film coating for tablets and caplets
US20040043072A1 (en) * 2002-09-04 2004-03-04 Will Joanne Patricia Alleviation of upper gastrointestinal irritation
BR0309691A (pt) * 2002-12-20 2005-08-02 Hoffmann La Roche Formulação de ibandronato em alta dose
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
JP4896480B2 (ja) * 2004-10-01 2012-03-14 第一三共ヘルスケア株式会社 陰イオン交換樹脂の粒子状組成物
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
EP3691646A4 (en) * 2017-10-02 2021-06-30 Board of Regents, The University of Texas System COMPOSITION TO INHALE OF CLOFAZIMINE AND THEIR METHODS OF USE

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2130794C3 (de) 1971-06-22 1974-07-11 Joh. A. Benckiser Gmbh, 6700 Ludwigshafen Verfahren zur Herstellung von l-Hydroxy-S-amino-propan-ljl-diphosphonsäure
DE2405254C2 (de) 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
JPS57177012A (en) * 1981-04-23 1982-10-30 Sumitomo Chem Co Ltd Preparation of chelate resin
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
ATE61371T1 (de) * 1986-11-21 1991-03-15 Ciba Geigy Ag Neue substituiertaminomethandiphosphonsaeuren.
US5057505A (en) * 1986-11-21 1991-10-15 Ciba-Geigy Corporation Substituted aminomethanediphosphonic acids and use in medicaments
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
PH27186A (en) 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate

Also Published As

Publication number Publication date
EP0566535A1 (de) 1993-10-20
AU665814B2 (en) 1996-01-18
ZA932613B (en) 1993-10-26
US5344825A (en) 1994-09-06
ES2137241T3 (es) 1999-12-16
FI931633A0 (fi) 1993-04-08
ATE183096T1 (de) 1999-08-15
EP0566535B1 (de) 1999-08-11
AU3696193A (en) 1993-10-21
IL105382A0 (en) 1993-08-18
NO931367L (no) 1993-10-18
DE59309727D1 (de) 1999-09-16
IL105382A (en) 1998-06-15
MX9302151A (es) 1993-10-01
KR940005268A (ko) 1994-03-21
NZ247398A (en) 1995-07-26
CA2093946C (en) 2005-07-05
NO931367D0 (no) 1993-04-14
TW237386B (da) 1995-01-01
CA2093946A1 (en) 1993-10-16
HU9301088D0 (en) 1993-06-28
NO306978B1 (no) 2000-01-24
HU219022B (hu) 2001-04-28
PH30733A (en) 1997-10-17
KR100307786B1 (ko) 2001-11-30
GR3031645T3 (en) 2000-02-29
FI931633A (fi) 1993-10-16
FI110920B (fi) 2003-04-30
JPH069408A (ja) 1994-01-18
HUT63766A (en) 1993-10-28
JP3970941B2 (ja) 2007-09-05

Similar Documents

Publication Publication Date Title
DK0566535T3 (da) Methandiphosphonsyre-præparater med ionbyttere
ZA892557B (en) Pharmaceutical composition for oral administration,based on a diphosphonic acid derivative
GR3022249T3 (en) Pharmaceutical preparation and process for its manufacture.
PL341055A1 (en) Novel form of a drug for oral administration of active compounds being unstable in acid environments
AU7534087A (en) Sustained release pharmaceutical compositions in oral dosage form
DE3863678D1 (de) Lithiumsalze enthaltende pharmazeutische zubereitungen.
ZA905861B (en) Pharmaceutical composition for oral administration containing nac
NO975634L (no) Stabile farmasöytiske preparater inneholdende tiludronathydrater og fremgangsmåte for fremstilling av farmasöytiske preparater
IL69164A0 (en) Diphosphonic acid derivatives,processes for the manufacture thereof and pharmaceutical preparations containing the same
AU4827085A (en) Method for treatment of antidiuresis employing serine derivatives
AU1179788A (en) Benzimidazoles, a process for their preparation and pharmaceutical preparations containing these compounds
HK1001822A1 (en) Medicinal form for oral application for the once-a-day treatment of hypertension by diltiazem hydrochloride
Mungavin et al. Comparison of two dosage regimens of trazodone(molipaxin) in the treatment of depression. A multicentre general practice study.
Cleland Microbleeding in 28-day naproxen controlled-release(Naprosyn SR) therapy.
Kuzmin et al. Pharmacokinetics of zixorine administered in single and multiple doses.
Ferrari et al. Eosinophilia associated with glaphenin.
Lessard Short Pieces for Piano (For Aaron)
EG21151A (en) A convenient facile synthesis of 2,6-dichlorod-iphenylamine the key intermediate for the synthesis of 0-(2,6 dichloroanilino) phenylacetic acid diclofenac voltaren) utilizing the firstly reported n- formyl-2,6-dichlorodiphenylamine
EP0356254A3 (en) Pharmaceutical formulations
ATE65182T1 (de) Lithiumsalze enthaltende pharmazeutische zubereitungen.